{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:34Z","timestamp":1792715854486,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.comppsych.2026.152744","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:38:57Z","timestamp":1788881937000},"page":"152744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antipsychotic-induced movement disorders among patients with severe mental illness in Africa: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"151","author":[{"given":"Zemene","family":"Yiglet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getasew","family":"Kibralew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilina","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worknew","family":"Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeneneh","family":"Workie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digafe","family":"Demelash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birtukan","family":"Fasil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abebayehu","family":"Sahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawit","family":"Demelash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wondale","family":"Endeshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulu","family":"Getnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulualem","family":"Kelebie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9831","key":"10.1016\/j.comppsych.2026.152744_bb0005","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.comppsych.2026.152744_bb0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ddr.21337","article-title":"Improving current treatments for schizophrenia","volume":"77","author":"Maric","year":"2016","journal-title":"Drug Dev Res"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41398-022-01904-2","article-title":"Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics","volume":"12","author":"Spark","year":"2022","journal-title":"Transl Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.comppsych.2026.152744_bb0025","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"issue":"7","key":"10.1016\/j.comppsych.2026.152744_bb0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"issue":"12","key":"10.1016\/j.comppsych.2026.152744_bb0045","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0006-3223(03)00170-7","article-title":"Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients","volume":"53","author":"Dolder","year":"2003","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0050","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152744_bb0055","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00004850-199803003-00009","article-title":"Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia","volume":"13","author":"Barnes","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"issue":"9657","key":"10.1016\/j.comppsych.2026.152744_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"9618","key":"10.1016\/j.comppsych.2026.152744_bb0070","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.comppsych.2026.152744_bb0075","article-title":"Vitamin E for antipsychotic-induced tardive dyskinesia","volume":"1","author":"Soares-Weiser","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.comppsych.2026.152744_bb0080","article-title":"Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia","volume":"4","author":"Adelufosi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0085","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41380-024-02733-z","article-title":"Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis","volume":"30","author":"Solmi","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-025-07645-y","article-title":"Prevalence and associated factors of antipsychotic-induced extrapyramidal symptoms in the Tigray region","volume":"25","author":"Gebremariam","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152744_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1745017902117010001","article-title":"Assessment of extrapyramidal symptoms associated with psychotropics pharmacological treatments, and associated risk factors","volume":"17","author":"Abu-Naser","year":"2021","journal-title":"Clin. Pract. Epidemiol. Mental Health: CP & EMH"},{"issue":"7","key":"10.1016\/j.comppsych.2026.152744_bb0100","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1017\/S0033291708004716","article-title":"Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review","volume":"39","author":"Pappa","year":"2009","journal-title":"Psychol Med"},{"issue":"5","key":"10.1016\/j.comppsych.2026.152744_bb0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis","year":"2018","journal-title":"Ther. Adv. Drug Safety"},{"key":"10.1016\/j.comppsych.2026.152744_bb0110","article-title":"Erratum: extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate","volume":"27","author":"Joubert","year":"2021","journal-title":"S Afr J Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomisedtrial","volume":"193","author":"Miller","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","article-title":"Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review","volume":"28","author":"Gao","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.comppsych.2026.152744_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257129","article-title":"Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies","volume":"16","author":"Ali","year":"2021","journal-title":"PloS One"},{"issue":"2\u20133","key":"10.1016\/j.comppsych.2026.152744_bb0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.schres.2005.07.032","article-title":"Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, central and Eastern Europe, and Latin America","volume":"81","author":"Kasper","year":"2006","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/YCO.0b013e3283413505","article-title":"Second-generation antipsychotics in major depressive disorder: update and clinical perspective","volume":"24","author":"Chen","year":"2011","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WNF.0000000000000040","article-title":"Antipsychotics-induced tardive syndrome: a retrospective epidemiological study","volume":"37","author":"Lee","year":"2014","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0145","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12888-025-07202-7","article-title":"Predictors of extrapyramidal side effects among patients taking antipsychotic medication at Mekelle psychiatry units, northern Ethiopia, 2023: unmatched case-control study","volume":"25","author":"Gebru","year":"2025","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/09638237.2020.1739242","article-title":"Spontaneous and emergent extrapyramidal syndromes in black Africans with first-episode schizophrenia and first exposure to antipsychotics","volume":"30","author":"Ojagbemi","year":"2021","journal-title":"J Ment Health"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00228-016-2166-2","article-title":"Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics","volume":"73","author":"Ribeiro","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.comppsych.2026.152744_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.comppsych.2026.152744_bb0170","unstructured":"Institute JB. Critical appraisal tools: The University of Adelaide; 2020Retrieved 10\/06\/22 from, https:\/\/jbi. global\/critical-appraisal-tools."},{"issue":"8","key":"10.1016\/j.comppsych.2026.152744_bb0175","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.11124\/JBIES-20-00267","article-title":"Prevalence of comorbid substance use disorders with anxiety disorders or post-traumatic stress disorder in people seeking treatment for substance abuse: a systematic review protocol","volume":"19","author":"Camp\u00ealo","year":"2021","journal-title":"JBI Evid Synthes"},{"issue":"7","key":"10.1016\/j.comppsych.2026.152744_bb0180","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-effect vs random-effects models for meta-analysis: 3 points to consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Global Spine J"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"issue":"5","key":"10.1016\/j.comppsych.2026.152744_bb0190","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/ije\/dyn065","article-title":"Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation","volume":"37","author":"Patsopoulos","year":"2008","journal-title":"Int J Epidemiol"},{"issue":"7109","key":"10.1016\/j.comppsych.2026.152744_bb0195","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"bmj"},{"key":"10.1016\/j.comppsych.2026.152744_bb0200","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s41782-021-00150-8","article-title":"Antipsychotics induced movement and sleep disorder on patients with schizophrenia attending follow-up service","volume":"6","author":"Kassaw","year":"2022","journal-title":"Sleep and Vigilance"},{"key":"10.1016\/j.comppsych.2026.152744_bb0210","first-page":"179","article-title":"Psychotropic medications-induced tardive dyskinesia and associated factors among patients with mental illness in Ethiopia","author":"Kumsa","year":"2020","journal-title":"Clin Pharmacol Adv Appl"},{"key":"10.1016\/j.comppsych.2026.152744_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-9338(12)75282-3","article-title":"P-1115-prevalence of conventional antipsychotic induced movement disorders and factors associated with them among psychotic patients treated at amanuel mental specialized hospital; aa, Ethiopia","volume":"27","author":"Taye","year":"2012","journal-title":"Eur Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2026.152744_bb0220","doi-asserted-by":"crossref","first-page":"76","DOI":"10.11648\/j.ajpn.20140205.12","article-title":"Antipsychotic medication induced movement disorders: the case of Amanuel specialized mental hospital, Addis Ababa, Ethiopia","volume":"2","author":"Taye","year":"2014","journal-title":"Am J Psychiatry Neurosci"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0225","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12888-014-0280-1","article-title":"Movement disorders in neuroleptic-na\u00efve patients with schizophrenia spectrum disorders","volume":"14","author":"Ayehu","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152744_bb0230","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2147\/NDT.S261272","article-title":"Drug-induced movement disorders and its associated factors among patients attending treatment at public hospitals in eastern Ethiopia","author":"Misgana","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0235","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12888-018-1999-x","article-title":"Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel mental specialized hospital, Central Ethiopia: cross-sectional study","volume":"19","author":"Wubeshet","year":"2019","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.schres.2004.10.009","article-title":"Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the eastern cape of South Africa","volume":"76","author":"Patterson","year":"2005","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0245","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/15504263.2020.1714099","article-title":"Methamphetamine use and antipsychotic-related extrapyramidal side-effects in patients with psychotic disorders","volume":"16","author":"Temmingh","year":"2020","journal-title":"J Dual Diagn"},{"issue":"9","key":"10.1016\/j.comppsych.2026.152744_bb0250","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.v64n0913","article-title":"Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol","volume":"64","author":"Oosthuizen","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152744_bb0255","article-title":"Neurological soft signs, spontaneous and treatment emergent extrapyramidal syndromes in black Africans with first episode schizophrenia","volume":"9","author":"Ojagbemi","year":"2018","journal-title":"Front Psych"},{"key":"10.1016\/j.comppsych.2026.152744_bb0260","first-page":"36","article-title":"Prevalence and pattern of drug-induced movement disorders in University of Port Harcourt Teaching Hospital (UPTH): a 3-year review","volume":"1","author":"Stanley","year":"2016","journal-title":"EC Neurol"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0265","doi-asserted-by":"crossref","first-page":"225","DOI":"10.20471\/dec.2023.59.02.06","article-title":"Prevalence and correlates of extrapyramidal side effects among patients with schizophrenia spectrum disorders on typical and atypical antipsychotics","volume":"59","author":"Shettima","year":"2023","journal-title":"Arch Psychiatry Res"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0270","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1192\/bjp.164.2.184","article-title":"Movement disorder in never and minimally treated Nigerian schizophrenic patients","volume":"164","author":"McCREADIE","year":"1994","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152744_bb0275","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.encep.2012.08.004","article-title":"Dyskin\u00e9sies tardives sous neuroleptiques classiques: \u00e0 propos d\u2019une population tunisienne de schizophr\u00e8nes","volume":"39","author":"Sejil","year":"2013","journal-title":"L\u2019Enc\u00e9phale"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0280","first-page":"48","article-title":"Acute drug-induced dystonia: emergency department presentation and management","volume":"38","author":"Hammami","year":"2026","journal-title":"Toxicol Anal Clin"},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0285","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/WNF.0000000000000506","article-title":"Akathisia among patients undergoing antipsychotic therapy: prevalence, associated factors, and psychiatric impact","volume":"45","author":"Jouini","year":"2022","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.comppsych.2026.152744_bb0290","series-title":"Factors associated with extrapyramidal side effects of first-generation antipsychotics: A cross-sectional study in Ugandan tertiary hospitals","author":"Kalume","year":"2024"},{"key":"10.1016\/j.comppsych.2026.152744_bb0295","series-title":"Prevalence of side effects of typical antipsychotic medications among patients admitted to the psychiatry unit of Kampala International University Teaching Hospital, Uganda","author":"Odoch","year":"2014"},{"issue":"10","key":"10.1016\/j.comppsych.2026.152744_bb0300","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4314\/eamj.v79i10.8819","article-title":"Prevalence of tardive dyskinesia among psychiatric in-patients at Mathari hospital, Nairobi","volume":"79","author":"Gatere","year":"2002","journal-title":"East Afr Med J"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0305","first-page":"133","article-title":"Prevalence and correlates of drug-induced extrapyramidal symptoms in patients with schizophrenia","volume":"3","author":"Sharma","year":"2025","journal-title":"Junior Res"},{"issue":"12","key":"10.1016\/j.comppsych.2026.152744_bb0310","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1474-4422(05)70226-X","article-title":"Prevalence of movement disorders in men and women aged 50\u201389 years (Bruneck study cohort): a population-based study","volume":"4","author":"Wenning","year":"2005","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0315","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","article-title":"Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used","volume":"197","author":"Pope","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.comppsych.2026.152744_bb0320","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/mds.29392","article-title":"Scales for antipsychotic-associated movement disorders: systematic review, critique, and recommendations","volume":"38","author":"Martino","year":"2023","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0325","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12246","article-title":"Extrapyramidal side effects of antipsychotics: prevalence and risk factors. Results from the national FACE-SZ cohort cover title extrapyramidal side effects and antipsychotics","volume":"80","author":"Misdrahi","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2026.152744_bb0330","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/JCP.0b013e3181f14098","article-title":"Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study","volume":"30","author":"Novick","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0335","article-title":"Pharmacovigilance in high-income countries: current developments and a review of literature","volume":"11","author":"Khan","year":"2023","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.comppsych.2026.152744_bb0340","series-title":"StatPearls [Internet]","article-title":"Extrapyramidal side effects","author":"D\u2019Souza","year":"2025"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0345","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s11845-023-03539-8","article-title":"Improving the clinical monitoring of extrapyramidal symptoms: a local quality improvement project","volume":"193","author":"Morgan","year":"2024","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.comppsych.2026.152744_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.593143","article-title":"Prevalence of extrapyramidal symptoms in in-patients with severe mental illnesses: focus on parkinsonism","volume":"11","author":"Roiter","year":"2020","journal-title":"Front Neurol"},{"issue":"S1","key":"10.1016\/j.comppsych.2026.152744_bb0355","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0924-9338(09)71244-1","article-title":"Prevalence of extrapyramidal side effects in patients receiving depot antipsychotic medication","volume":"24","author":"Luft","year":"2009","journal-title":"Eur Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0360","first-page":"254","article-title":"Integrating incidence and prevalence of tardive dyskinesia","volume":"22","author":"Kane","year":"1986","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0365","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0370","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.comppsych.2026.152744_bb0375","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2215-0366(20)30264-9","article-title":"Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis","volume":"7","author":"Rubio","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0380","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/YIC.0000000000000125","article-title":"Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy","volume":"31","author":"Alphs","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"issue":"1\u20133","key":"10.1016\/j.comppsych.2026.152744_bb0385","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.schres.2011.10.021","article-title":"Five-year clinical course and outcome of schizophrenia in Ethiopia","volume":"136","author":"Teferra","year":"2012","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0390","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/wps.20374","article-title":"Updating the research domain criteria","volume":"15","author":"Sanislow","year":"2016","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.comppsych.2026.152744_bb0395","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1474-4422(19)30152-8","article-title":"Recent developments in drug-induced movement disorders: a mixed picture","volume":"18","author":"Factor","year":"2019","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0400","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.focus.18402","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"18","author":"Keepers","year":"2020","journal-title":"Focus"},{"key":"10.1016\/j.comppsych.2026.152744_bb0405","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.154.5.672","article-title":"Barnes akathisia rating scale","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0410","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00004850-200015040-00004","article-title":"Clinical correlates of akathisia in acute psychiatric inpatients","volume":"15","author":"Berardi","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2026.152744_bb0415","doi-asserted-by":"crossref","DOI":"10.1177\/20451253221139608","article-title":"Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan","volume":"12","author":"Mori","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.comppsych.2026.152744_bb0420","unstructured":"Maheshwary A, Bhatti KS. Dystonic React."},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0425","first-page":"391","article-title":"Drug-induced extrapyramidal syndromes: implications for contemporary practice","volume":"39","author":"Caroff","year":"2016","journal-title":"Psychiatr Clin"},{"issue":"7210","key":"10.1016\/j.comppsych.2026.152744_bb0430","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.319.7210.623","article-title":"Acute dystonia induced by drug treatment","volume":"319","author":"Van Harten","year":"1999","journal-title":"Bmj"},{"key":"10.1016\/j.comppsych.2026.152744_bb0435","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"10.1016\/j.comppsych.2026.152744_bb0440","first-page":"612","article-title":"Comparative study of extrapyramidal side effects, sexual dysfunctions and hyperprolactinaemia using typical and atypical antipsychotic medications among patients with schizophrenia in Maiduguri","volume":"64","author":"Shettima","year":"2023","journal-title":"Niger Med J"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0445","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13651501.2017.1381268","article-title":"Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India\u2013a cross-sectional study","volume":"22","author":"Desai","year":"2018","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"11","key":"10.1016\/j.comppsych.2026.152744_bb0450","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0706743718786702","article-title":"Antipsychotic drug-induced movement disorders: a forgotten problem?","volume":"63","author":"Pringsheim","year":"2018","journal-title":"Can J Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0455","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.comppsych.2026.152744_bb0460","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s12325-019-01201-3","article-title":"Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature","volume":"37","author":"Farkouh","year":"2020","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.comppsych.2026.152744_bb0465","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2710.1999.00246.x","article-title":"Gender-related differences in pharmacokinetics and their clinical significance","volume":"24","author":"Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0470","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/j.1755-5949.2010.00163.x","article-title":"Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"S\u00e1nchez","year":"2010","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0475","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1385\/ENDO:21:1:67","article-title":"Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies","volume":"21","author":"Dluzen","year":"2003","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0480","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/2141-9248.109499","article-title":"Prevalence and correlates of \u201chigh dose\u201d antipsychotic prescribing: findings from a hospital audit","volume":"3","author":"Adesola","year":"2013","journal-title":"Ann Med Health Sci Res"},{"issue":"8","key":"10.1016\/j.comppsych.2026.152744_bb0485","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152744_bb0490","first-page":"25","article-title":"Pathophysiology of antipsychotic drug-induced movement disorders","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0495","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.comppsych.2026.152744_bb0500","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0505","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.psc.2012.06.007","article-title":"Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice","volume":"35","author":"Correll","year":"2012","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.comppsych.2026.152744_bb0510","series-title":"Stahl\u2019s essential psychopharmacology: Neuroscientific basis and practical applications","author":"Stahl","year":"2021"},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0515","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2026.152744_bb0520","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2018-100026","article-title":"Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia","volume":"32","author":"Weng","year":"2019","journal-title":"General Psychiatr"},{"issue":"9","key":"10.1016\/j.comppsych.2026.152744_bb0525","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00044011-200222090-00006","article-title":"Frequency of extrapyramidal adverse reactions in schizophrenic outpatients treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study","volume":"22","author":"Bobes","year":"2002","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0530","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0269881105051539","article-title":"Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness","volume":"19","author":"Honer","year":"2005","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.comppsych.2026.152744_bb0535","unstructured":"De Santis M. The long-term effects of chronic antipsychotic drug treatment in juvenile rats on adult behavioural attributes, Dopamine and Serotonin Neurotransmitter Systems: University of Wollongong."},{"issue":"4","key":"10.1016\/j.comppsych.2026.152744_bb0540","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2026.152744_bb0545","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"issue":"6","key":"10.1016\/j.comppsych.2026.152744_bb0550","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp.2005.079228","article-title":"Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder","volume":"77","author":"Potvin","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.comppsych.2026.152744_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/S1353-8020(13)70027-0","article-title":"Acute and subacute drug-induced movement disorders","volume":"20","author":"Burkhard","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"S1","key":"10.1016\/j.comppsych.2026.152744_bb0560","doi-asserted-by":"crossref","DOI":"10.1017\/S0317167100003309","article-title":"Antipsychotic drug-induced movement disorders","volume":"30","author":"Blanchet","year":"2003","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"10.1016\/j.comppsych.2026.152744_bb0565","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.mp.4001507","article-title":"Dopamine in drug abuse and addiction: results from imaging studies and treatment implications","volume":"9","author":"Volkow","year":"2004","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2026.152744_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/wfs2.1340","article-title":"Alcohol, its absorption, distribution, metabolism, and excretion in the body and pharmacokinetic calculations","volume":"1","author":"Jones","year":"2019","journal-title":"Wiley Interdiscip Rev Forensic Sci"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X26000830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X26000830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:39:22Z","timestamp":1792712362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X26000830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":114,"alternative-id":["S0010440X26000830"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2026.152744","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic-induced movement disorders among patients with severe mental illness in Africa: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2026.152744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152744"}}